Literature DB >> 6343871

Association of adrenocorticosteroid therapy and peptic-ulcer disease.

J Messer, D Reitman, H S Sacks, H Smith, T C Chalmers.   

Abstract

We reexamined the association between corticosteroid therapy and subsequent peptic ulceration or gastrointestinal hemorrhage by pooling data from 71 controlled clinical trials in which patients were randomized to systemic corticosteroids (or ACTH) or to nonsteroid therapy. Of 3064 steroid-treated patients evaluated for peptic ulcer, 55 (1.8 per cent) had ulcers, as compared with 23 of 2897 controls (0.8 per cent) (relative risk, 2.3; 95 per cent confidence interval, 1.4 to 3.7). Of 3135 steroid-treated patients evaluated for gastrointestinal hemorrhage, 78 (2.5 per cent) had bleeding, as compared with 48 of 2976 controls (1.6 per cent) (relative risk, 1.5; 95 per cent confidence interval, 1.1 to 2.2). The incidence of ulcers varied directly with the dosage of steroids. When separate analyses were performed for studies that were double-blind, used only oral steroids, used only parenteral steroids, or excluded patients with a history of ulcer, the trend remained consistent but did not always reach statistical significance. This study strongly suggests that corticosteroids do increase the risk of peptic ulcers and gastrointestinal hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343871     DOI: 10.1056/NEJM198307073090105

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

1.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

2.  Factors associated with the initiation of proton pump inhibitors in corticosteroid users.

Authors:  Jeffrey C Munson; Peter M Wahl; Gregory Daniel; Stephen E Kimmel; Sean Hennessy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01-25       Impact factor: 2.890

3.  Current management of corticosteroid-induced osteoporosis: variations in awareness and management.

Authors:  J G Ryan; R K Morgan; P J Lavin; F E Murray; P G O'Connell
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

Review 4.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use.

Authors:  J Nash; L Lambert; M Deakin
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

6.  Corticosteroids in the management of central nervous system tumours. Kids Neuro-Oncology Workshop (KNOWS).

Authors:  A W Glaser; N Buxton; D Walker
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

7.  Thomas C Chalmers (1917-1995): a pioneer of randomised clinical trials and systematic reviews.

Authors:  Kay Dickersin; Frances Chalmers
Journal:  J R Soc Med       Date:  2015-06       Impact factor: 5.344

8.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

Review 9.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 10.  Systemic corticosteroid therapy--side effects and their management.

Authors:  R M Stanbury; E M Graham
Journal:  Br J Ophthalmol       Date:  1998-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.